Ajinomoto AminoScience Builds Upon Success Expressing Complex Proteins with CorynexTM Expression System

Ajinomoto AminoScience Builds Upon Success Expressing Complex Proteins with CorynexTM Expression System
CorynexTM Expresses Correctly Folded Protein Directly into Culture Medium

RALEIGH, NC - August 23, 2011- Ajinomoto AminoScience LLC (http://www.ajiaminoscience.com/Default.aspx) (AAS) today announced the availability of a case study profiling how one global pharmaceutical company relied on its CorynexTMRecombinant Protein Expression System (http://www.ajiaminoscience.com/products/branded_products/corynex.aspx) to express and purify proteins. This new case study further builds upon Ajinomoto's proven success (http://www.corynex.com/pdfs/case_study_viable-protein-opps.pdf) expressing complex proteins with the CorynexTM Expression System.
Download your complete copy at www.corynex.com .

Initially, the global pharma company had difficulty expressing and purifying a particularly difficult protein via traditional e-coli and yeast-based expression systems.  Since the pharma company was only able to express misfolded forms and aggregates, they became interested in testing whether Ajinomoto's proprietary CorynexTM Expression System (http://www.corynex.com) was capable of expressing the correctly folded protein that could then be purified.  This system uses the gram-positive Corynebacterium glutamicum to express folded active proteins directly into media, thus reducing purification steps and potential difficulties, lowering costs, and increasing yield. 

Ultimately, Ajinomoto was able to demonstrate that CorynexTM can express correctly folded protein directly into the broth, whereas the customer could not. In addition, CorynexTM enabled the optimization of expression levels of the correctly folded protein, resulting in a significant cost advantage for the customer.

With this most recent success, Ajinomoto added to its knowledge base by understanding which proteins (size, complexity, characteristics, and uses) the CorynexTM Expression System can or cannot successfully express and translocate into the broth. Ajinomoto's cumulative knowledge creates the possibility of licensing opportunities for pharma companies looking to bring the CorynexTM Expression System in-house for the development of other proprietary proteins.

To read more about the successes the company has experienced using Ajinomoto's CorynexTM (http://www.corynex.com) , including reduced contamination, faster production times, as well as lessons learned from non-expressed proteins, please visit www.corynex.com .  In addition to the case study, you can also download a related whitepaper, "Speeding and Simplifying Recombinant Protein Production" and view video animation of the expression and export of recombinant proteins from Corynebacterium glutamicum.

About Ajinomoto AminoScience, LLC
Ajinomoto is the leading supplier of pharmaceutical and research-grade amino acids in the US and throughout the world.  Leveraging its unrivaled foundation of more than 50 years of experience identifying, refining, and marketing amino acids, Ajinomoto AminoScience, LLC (AAS) continues to innovate and set new industry standards for manufacturing and related services within the fermentation and expression fields.  Building on its legacy, AAS has transitioned the same level of quality and performance into new core competencies in the areas of recombinant protein expression and peptide synthesis.  These new processes enable pharmaceutical and bio-tech companies to develop high-quality products that were previously thought to be too complicated or expensive to produce.  The CorynexTM (http://www.ajiaminoscience.com/Products/Corynex.aspx) Recombinant Protein Expression System is a streamlined, more efficient process to produce complex human proteins for pharmaceutical use using a specially-developed gram-positive bacterium, Corynebacterium glutamicum.  The AjiPhase (http://www.ajiphase.com) TM service enables the use of a single peptide synthesis methodology throughout therapeutic peptide development as peptide requirements increase.  Ajinomoto AminoScience, LLC is a part of Ajinomoto USA Inc., a wholly-owned subsidiary of Ajinomoto Co., Inc.  For more information on AAS and its products and services, please refer to http://www.ajiaminoscience.com/Default.aspx## .

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.